New formulation approved.(The Private Eye)(Brief Article)

Private Label Buyer, October, 2004

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) of New Delhi, India, announced that RLL received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets. The Division of Bioequivalence determined that the tablets are the bioequivalent of the branded drug Claritin-D 24-Hour Extended Relief Tablets made by the Schering Corp., sales of which were $64.5 million over the last year.

Loratadine and Pseudoephedrine Sulfate Extended Relief Tablets offer temporary relief of symptoms such as nasal congestion, runny nose, sneezing, itchy and watery eyes due to hay fever or other allergies. The drugs also temporarily relieve sinus...